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Purpose: This evidence mapping aims to describe and assess the quality of available evidence 
in systematic reviews (SRs) on treatments for oral cancer.
Materials and methods: We followed the methodology of Global Evidence Mapping. Searches 
in MEDLINE, EMBASE, Epistemonikos and The Cochrane Library were conducted to identify 
SRs on treatments for oral cancer. The methodological quality of SRs was assessed using the 
Assessing the Methodological Quality of Systematic Reviews-2 tool. We organized the results 
according to identified Population–Intervention–Comparison–Outcome (PICO) questions and 
presented the evidence mapping in tables and a bubble plot.
Results: Fifteen SRs met the eligibility criteria, including 118 individual reports, of which 
55.1% were randomized controlled clinical trials. Ten SRs scored “Critically low” methodologi-
cal quality. We extracted 30 PICOs focusing on interventions such as surgery, radiotherapy, 
chemotherapy, targeted therapy and immunotherapy; 18 PICOs were for resectable oral cancer, 
of which 8 were reported as beneficial. There were 12 PICOs for unresectable oral cancer, of 
which only 2 interventions were reported as beneficial.
Conclusion: There is limited available evidence on treatments for oral cancer. The method-
ological quality of most included SRs scored “Critically low”. The main beneficial treatment 
reported by authors for patients with resectable oral cancer is surgery alone or in combination 
with radiotherapy or chemotherapy. Evidence about the benefits of the treatments for unresectable 
oral cancer is lacking. These findings highlight the need to address future research focused on 
new treatments and knowledge gaps in this field, and increased efforts are required to improve 
the methodology quality and reporting process of SRs on treatments for oral cancer.
Keywords: mouth neoplasms, oral carcinoma, buccal tumor, evidence synthesis, evidence-
based medicine
Introduction
Oral cancer is one of the most prevalent cancers worldwide. Oral squamous cell 
carcinoma is the most common cancer occurring in the mouth, with an estimate of 
300,000 new cases globally each year; only in the US, there were around 50,000 new 
cases expected in 2017.1 Oral cancer is posing an ever-increasing threat to global 
health and represents a growing burden on health services, which is a major problem 
in some parts of the world, especially in developing countries. Risk factors for oral 
cancer are frequently associated with lifestyle habits, such as smoking, alcohol abuse, 
poor nutrition and the use of betel quid.2
Unfortunately, the overall prognosis in these patients is low, with a 5-year 
survival rate of 50%, which has not changed over the last decades despite the 
advances in oncology treatment.3 Locoregionally advanced oral cavity cancers are 
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aggressive tumors with high probabilities of relapse after 
definitive treatment with surgery or radiotherapy. There-
fore, a multimodal approach, combining surgery and 
postoperative radiotherapy or chemoradiotherapy, has 
been suggested.4,5
Currently, there is a vast published scientific literature 
proposing a variety of treatment approaches for oral cancer. 
This fact may hinder knowing the effectiveness of such 
therapies and when they should be used. Furthermore, some 
research may be influenced by conflicts of interest. Thus, a 
critical analysis and a methodological quality assessment of 
the available evidence are required. In this sense, one of the 
options to organize and critically assess published studies is 
systematic reviews (SRs), which summarize the results of the 
evidence from health care primary studies in order to answer 
a specific research question.6
Likewise, there are new tools for evidence synthesis, such 
as evidence mapping, scoping reviews and rapid reviews, 
which have been developed to help clinicians, patients, 
researchers and other stakeholders to make evidence-based 
decisions.7 These new options are appropriate to address 
issues that may be too extensive for an SR.8
In 2007, the Global Evidence Mapping (GEM) 
init iat ive was established as a collaboration of 
clinical research and policy stakeholders to provide an 
overview of existing research about traumatic brain injury 
and spinal cord injury.9 Evidence mapping provides an 
innovative and visual approach to establish what we know 
and do not know about the effects of interventions on a 
thematic area. It can support evidence-informed decision 
making by facilitating evidence from existing SRs in a 
user-friendly format.7,10
The aim of this evidence mapping is to identify, describe 
and organize the current available evidence in SRs regard-
ing therapeutic interventions for oral cancer. This approach 
purposes to determine the clinical questions assessed in the 
scientific literature and the corresponding quality of the 
supporting evidence, as well as to give general information 
about their claimed effectiveness. This information shall 




This evidence mapping adhered to the PRISMA-Extension 
for Scoping Reviews.11 It was carried out in accordance with 
the methodology proposed by GEM,9 adding some previously 
suggested tasks.12 All methods were specified a priori in a 
protocol (available on request).
eligibility criteria
We included SRs published any year, with or without 
meta-analysis, assessing any therapeutic interventions in 
patients diagnosed with oral cavity cancer defined by the 
ICD for Oncology13 with codes C01–C02, C03, C04 and 
C05–C06. SRs related to head and neck cancer (C00–C14) 
with cases of oral cancer were included (as long as at least 
50% of the participants had oral cavity cancer, or data for 
this cancer alone were available separately). Included SRs 
had conducted a comprehensive search in at least two dif-
ferent databases and reported the assessment of risks of bias 
or quality of their included studies.6 When several articles 
published by the same team were identified, we considered 
the most recent publication. Conversely, SRs about prog-
nosis, safety or cost-effectiveness were excluded.
search strategy
We searched for systematic literature in MEDLINE (via 
PubMed), EMBASE (via Ovid), Epistemonikos, The 
Cochrane Database of Systematic Reviews (via The Cochrane 
Library) and Database of Abstracts of Reviews of Effects and 
Health Technology Assessments (via The Cochrane Library). 
The latest search was conducted on October 25, 2018.
We used MeSH descriptor and free text terms for oral 
cavity cancer, such as “mouth neoplasms”, “oral carcinoma”, 
“oral cancer”, “oral tumor”, “buccal carcinoma”, and thesau-
rus terms when available. We adapted the search strategy in 
accordance with the specific characteristics of each database 
(Supplementary material 1) with no language restrictions. In 
addition, a cited reference search was conducted.
sR selection
We managed all retrieved titles and abstracts with the refer-
ence manager software EndNote® (Version X7, Thomson 
Reuters). After removing duplicates, two reviewers (MMA 
and JVAF) independently screened all titles/abstracts to 
exclude irrelevant studies. Then, full articles were obtained 
for a final decision. Detailed reasons for exclusion of any 
study considered relevant were clearly stated.
Methodological quality assessment
The report of methodological quality for each SR was 
assessed with the Assessing the Methodological Quality 
of Systematic Reviews (AMSTAR)-2 tool, a validated 
16-item instrument for critically appraising SRs.14 It has 
an overall rating based on weaknesses in critical domains 
(items: 2, 4, 7, 9, 11, 13 and 15). Briefly, the overall con-
fidence in the results of the SR is rated in the following 
four categories: “High”, no or one non-critical weakness; 
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“Moderate”, more than one non-critical weakness; “Low”, 
one critical flaw with or without non-critical weaknesses 
and “Critically low”, more than one critical flaw with or 
without non-critical weaknesses.
Data extraction
General characteristics of the SR: authors, publication year, 
type of SR (with or without meta-analysis), objective, search 
date, design and number of included studies, and number of 
included participants.
Characteristics of research questions: we identified the 
research questions of each SR based on the aims stated 
by the authors, the eligibility criteria and the conclusions 
of the SR. The research questions were drawn using the 
PICO framework, which specifies the four key components 
of a well-defined therapeutic question: population, inter-
vention, comparison and outcomes.6 A research question 
was considered if all the elements of the PICO framework 
were provided and a conclusion about the direction of the 
effect was described anywhere in the SR. We extracted 
details on the population characteristics (eg, adult popu-
lation, type of cancer, stage and cancer location), the 
intervention and comparator (eg, type of intervention and 
comparison broadly categorized as chemotherapy, surgery, 
radiotherapy, immunotherapy and targeted therapy) and 
the outcomes.
The conclusions of the SR authors were classified into five 
categories following previously reported criteria.12 Briefly, 
the “beneficial” category was used if there were conclusions 
with evidence of a positive effect and SR authors used a lan-
guage clearly indicative of a beneficial effect without major 
concerns regarding the existing evidence. The “probably 
beneficial” category was used for those conclusions where 
the evidence base was insufficient to draw firm conclusions 
despite the positive treatment effect and the reporting sug-
gested a benefit. The “harmful” category was used when 
the reporting of the conclusions was clearly indicative of 
a harmful effect. The “no differential effect” category was 
used for conclusions that provided evidence for no difference 
between the intervention and the comparator. Finally, the 
“inconclusive” category was used if the direction of results 
was different across or within reviews due to conflicting 
results or limitations of individual studies.
Two authors (MMA and JVAF) independently performed 
all processes of study selection, methodological quality 
assessment and data extraction. If there were any disagree-
ments, these were resolved by consensus, and when necessary, 
an additional reviewer (GUC) participated in the discussion 
until an agreement was reached. If needed, we contacted the 
SR authors for clarification or to obtain missing information.
evidence mapping presentation
We presented the evidence mapping on tables describing the 
characteristics of the included SRs and on other tables provid-
ing the characteristics of all identified PICOs. We performed 
a narrative description of the PICOs stratified by disease 
severity (resectable and nonresectable cancers). In addition, 
we designed a bubble plot where each bubble represents one 
SR. This chart displays information in three dimensions: 1) 
the rating of authors’ conclusions represented in the x-axis as 
“beneficial”, “probably beneficial”, “harmful”, “no differen-
tial effect” and “inconclusive”; 2) AMSTAR-2 assessment in 
y-axis and 3) the number of primary studies included in the 
SR, which is shown in each bubble and is represented by the 
bubble size. Each bubble also represents a pie showing the 
proportion of randomized controlled trials (RCTs) included 
using a black bold line.
Results
studies selected
The research yielded 2,547 records after removing dupli-
cates. After title and abstract screening, 127 articles were 
obtained for final full-text review; 15 SRs15–29 met the 
eligibility criteria (Figure 1). The list of excluded studies 
along with exclusion rationale is available in Supplemen-
tary material 2.
Characteristics of the included sRs
Thirteen SRs15,16,18–27,29 included a meta-analysis, and all 
SRs15–29 were published in English between 2010 and 2018. 
Nine SRs15,19,22–26,28,29 had focused on oral cavity cancer 
exclusively, whereas other six SRs16–18,20,21,27 had focused on 
head and neck cancers, with the oropharyngeal cancer being 
the most frequent among them. Eight SRs15,17,19,22,24,27–29 
assessed surgical interventions, three SRs16,21,25 assessed 
radiotherapy, three SRs20,23,26 assessed chemotherapy and 
one SR18 assessed targeted therapy and immunotherapy. SRs 
included primary studies conducted from 1969 to 2015; the 
number of patients included in each SR ranged from 309 to 
16,767 adult individuals. This evidence mapping included 
118 reports of primary studies (Supplementary material 
3) with 10,423 participants after considering the overlap-
ping or duplication of studies. These studies included 65 
(55.1%) RCTs (n=5,724), 48 (40.7%) observational studies 
(n=42,396) and 5 (4.2%) controlled clinical trials (n=460). 
Table 1 shows the characteristics of included SRs.
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The methodological quality of sRs
Ten SRs15,19,22–29 scored “Critically low”, three SRs16,20,21 
scored “Low” and only two SRs17,18 scored “High” meth-
odological quality, according to the AMSTAR-2 critical 
appraisal criteria (Figure 2). The SRs were downgraded 
mainly because the SR authors did not explain their selec-
tion of the study designs for inclusion in the review,16–23,25–29 
sources of funding for the included studies were not clearly 
stated,15,16,19,22–29 there was no reference to a protocol,15,19,22–29 
and the list of excluded studies was not provided.15,19,22,24–27,29
Characteristics of PiCOs from sRs
The evidence mapping of the therapeutic interventions for 
oral cancer is presented in Figure 3; 30 PICOs were extracted, 
which focused on two population groups: patients with 
resectable oral cancers and patients with unresectable cancer.
Patients with resectable oral cancers
Thirteen SRs15,17–24,26–29 were conducted including 18 PICOs. 
Eight PICOs evaluated surgical interventions,17,19,22,24,27–29 five 
PICOs assessed chemotherapy,20,23,26 three PICOs assessed 
radiotherapy17,21 and two PICOs assessed immunotherapy.18 
Eight PICOs were reported as “beneficial”, one PICO as 
“probably beneficial”, eight PICOs as “no differential effect” 
and one PICO was reported as “inconclusive” (Table 2).
Interventions reported as “beneficial” were as follows: 
1) the elective neck dissection was better than no elective 
neck dissection in patients with negative neck nodes in terms 
of cervical metastasis rate, overall 5-year survival rate and 
occult cervical metastasis;28 2) the incontinuity neck dissec-
tion was better than discontinuous neck dissection in terms of 
local recurrence;29 3) a wider pathological margin (≥5 mm) 
was better than a narrow pathological margin (<5 mm) in 
terms of local recurrence rates in patients with oral squamous 
cell carcinoma treated by primary surgery without adjuvant 
therapy;15 4) radiotherapy combined with surgery was better 
than radiotherapy alone in terms of total mortality;17 5) the 
use of intra-arterial bleomycin and vincristine combined with 
surgery was better than surgery alone in terms of overall 
survival;20 6) post-surgery chemotherapy using methotrexate 
as chemotherapy drug was better than surgery alone in terms 
of total mortality;20 7) induction chemotherapy followed by 
surgery with or without radiotherapy was better than sur-
gery with or without radiotherapy in patients with positive 
Figure 1 PRISMA flow diagram detailing the selection process.
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Wrong study design: 30
Only one database included: 4
No therapeutic interventions: 9
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sRM not given To determine whether a wider pathological 
margin reduces local recurrence rates in 
patients with OsCC treated by primary surgery 
without adjuvant therapy





To study the effects of altered fractionation 
radiotherapy vs conventional radiotherapy on 
overall survival rates





To determine which surgical treatment 
modalities for oral cavity and oropharyngeal 
cancers result in increased overall survival, 
disease-free survival, progression-free survival 
and reduced recurrence
RCT: 7 669 high




To assess the effects of molecularly targeted 
therapies and immunotherapies, in addition to 
standard therapies, for the treatment of oral 
cavity or oropharyngeal cancers
RCT: 12 2,488 high





To compare elective neck dissection with 
observation or therapeutic neck dissection 
specifically in patients with early-stage OSCC 
and clinically n0 neck to explore the potential 









To determine whether chemotherapy, in 
addition to radiotherapy and/or surgery for 
oral cavity and oropharyngeal cancer, results in 
increased overall survival, disease-free survival, 
progression-free survival, locoregional control 
and reduced recurrence
RCT: 89 16,767 low
glenny et 
al, 201021
sRM July 2010 To determine which radiotherapy regimens for 
oral cavity and oropharyngeal cancers result in 
increased overall survival, disease-free survival, 
progression-free survival and locoregional 
control
RCT: 30 6,536 low
gou et al, 
201822
sRM May 2016 To explore the survival rate and disease control 
in patients with histological evidence of bone 
invasion and to compare the differences in 
survival rate and disease control between 
patients who underwent marginal mandibular 
resection and those who underwent segmental 
mandibulectomy
Cohort: 15 1,672 Critically low
lau et al, 
201623
sRM March 2016 To analyze the effect of induction 
chemotherapy in OsCC treatment by 
performing an updated sR and cumulative 
meta-analysis
RCT: 27 2,872 Critically low
liang et al, 
201524
sRM april 2015 To access the feasibility of selective neck 
dissection in oral cancer patients with positive 
neck nodes
Cohort: 5 443 Critically low
liu et al, 
201325
sRM June 2012 To compare the efficacy and safety of high-
dose rate and low-dose rate brachytherapy in 









To assess the effectiveness and safety of 
induction chemotherapy prior to surgery for 
untreated OsCC patients
RCT: 2 451 Critically low
(continued)
























To compare the prognoses outcomes 
of mandibular preservation method and 
the mandibulotomy approach in oral and 
oropharyngeal cancer patients
Cohort: 6 309 Critically low
Tang and 
leung, 201628
sR February 2015 To answer the clinical question, “When should 
elective neck dissection be performed in maxillary 
gingival and alveolar squamous cell carcinoma with 
negative neck nodes?”
Cohort: 10 506 Critically low
Wang et al, 
201829
sRM March 2017 To perform a meta-analysis to compare 
discontinuous neck dissection with incontinuity 
neck dissection as a treatment modality for sCC of 
the tongue and floor of the mouth
Cohort: 8 796 Critically low
Abbreviations: aMsTaR-2, assessing the Methodological Quality of systematic Reviews-2; OsCC, oral squamous cell carcinoma; RCT, randomized controlled trial; sCC, 
squamous cell carcinoma; sR, systematic review; sRM: systematic review with meta-analysis.
Figure 2 Methodological quality of the included systematic reviews.



























Anderson et al, 2015 CL
Baujat et al, 2010 L
Besell et al, 2011 H
Chan et al, 2015 H
Ding et al, 2018 CL
Furness et al, 2011 L
Glenny et al, 2010 L
Gou et al, 2018 CL
Lau et al, 2016 CL
Liang et al, 2015 CL
Liu et al, 2013 CL
Marta et al, 2015 CL
Pang et al, 2016 CL
Tang and Leung,  2016 CL
Wang et al, 2018 CL
Items
1. Did the research questions and inclusion criteria for the review
include the components of PICO?
2. Did the report of the review contain an explicit statement that the
review methods were established prior to the conduct of their review, and
did the report justify any significant deviations from the protocol?*
3. Did the review authors explain their selection of the study designs for
inclusion in the review?
4. Did the review authors use a comprehensive literature search
strategy?*
5. Did the review authors perform study selection in duplicate?
6. Did the review authors perform data extraction in duplicate?
7. Did the review authors provide a list of excluded studies and justify
the exclusions?*
8. Did the review authors describe the included studies in adequate
detail?
9. Did the review authors use a satisfactory technique for assessing the
risk of bias (RoB) in individual studies that were included in the review?*
10. Did the review authors report on the sources of funding for the
studies included in the review?
11. If meta-analysis was performed, did the review authors use
appropriate methods for statistical combination of results?*
12. If meta-analysis was performed, did the review authors assess the
potential impact of RoB in individual studies on the results of the meta-
analysis or other evidence synthesis?
13. Did the review authors account for RoB in individual studies when
interpreting/discussing the results of the review?*
14. Did the review authors provide a satisfactory explanation for, and
discussion of, any heterogeneity observed in the results of the review?
15. If they performed quantitative synthesis, did the review authors carry
out an adequate investigation of publication bias (small study bias) and
discuss its likely impact on the results of the review?*
16. Did the review authors report any potential sources of conflict of
interest, including any funding they received for conducting the review?
*Critical domain
Yes H: High
Partial Yes M: Moderate
No L: Low



































nodules classified as level II, in terms of overall survival26 
and 8) the use of recombinant interleukin-2 plus surgery 
was better than surgery alone in terms of overall survival.18
Patients with unresectable cancer
Six SRs16,18,20,21,23,25 were conducted including 12 PICOs. 
Nine PICOs assessed chemotherapy,20,23 two PICOs assessed 
radiotherapy16,21,25 and one  PICO assessed targeted therapy.18 
Two PICOs were reported as “beneficial”, two PICOs as 
“probably beneficial” and eight PICOs were reported as “no 
differential effect” (Table 3).
The interventions reported as “beneficial” were: 1) 
altered fractionation radiotherapy was better than conven-
tional radiotherapy in terms of overall survival16 and 2) 
bleomycin was better than methotrexate in terms of tumor 
regression.20
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Figure 3 evidence mapping of the therapeutic interventions for oral cancer.
Notes: (A) interventions for resectable oral cancer. (B) interventions for unresectable oral cancer. Bubble plots where each bubble represents one sR. The number of 
individual studies included in the sR is shown in each bubble and is represented by the bubble size. each bubble also represents a pie showing the proportion of randomized 
controlled trials included with a black bold line. *Two PICOs included this comparison, but the intervention was reported as “beneficial” only in the PICO for patients with 
positive neck nodes level ii. The number of individual studies included in the sR is shown in each bubble and is represented by the bubble size.
Abbreviations: 5-FU, 5-fluorouracil; BCG-CWP, Bacillus Calmette-Guérin-cell wall preparation; CCRT, concomitant chemo-radiotherapy; CT, chemotherapy; END, 






















































END vs Not receive an END
END vs Observation/therapeutic delayed neck dissection Pre- and postoperative RT vs Postoperative RT
Preoperative RT vs Surgery
Bleomycin + Vincristine + Surgery vs Surgery
Post-surgery CT vs Postoperative RT
Post-surgery CT vs Surgery
*ICT+surgery±RT vs Surgery±RT
Recombinant interleukin-2+surgery vs Surgery
BCG-CWP+surgery vs Surgery
Selective neck dissection vs Comprehensive neck dissection
Incontinuity neck dissection vs Discontinous neck dissection
Mandibular preservation vs Mandibulotomy
Marginal mandibulectomy vs Segmental mandibulectomy
Pathological margin≥5 mm vs Pathological margin<5 mm
Pathological margin≥10 mm vs Pathological margin<10 mm
High-dose rate brachytherapy vs Low-dose rate brachytherapy
Altered fractioned RT vs Conventional RT
ICT+RT vs RT
ICT+CCRT vs CCRT
MTX+RT vs RT MTX+5-FU(simultaneous) vs MTX+5FU (sequential)
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Discussion
Evidence mapping is a relatively new tool used to summarize 
available scientific evidence about a specific topic. However, 
although there is no standard definition of it or consensus 
about its components or the methods to be used, there are 
common characteristics for these types of review.7 In gen-
eral, it includes a systematic search covering a broad field to 
identify gaps in knowledge and/or future research needs. It 
also presents results in a user-friendly format, often a visual 
figure or graph, or a searchable database.7 Evidence mapping 
can produce an extensive list of prioritized research questions 
in a topic area, even in the absence of study retrieval and data 
extraction. It is a potential springboard for research, policy 
development and research funding.9
This evidence mapping may be the first one about 
therapeutic interventions for oral cancer because we found 
no previous reports. We decided to use this methodology 
developed by GEM initiative since it is rational and system-
atic.9 Recently, a report stated that most of the documents 
that met the common characteristics of evidence mapping 
referenced this methodology.7 The referenced methodol-
ogy includes three core tasks: setting the boundaries and 
context of the topic area in question, searching and select-
ing relevant studies and reporting on search results and 
study characteristics.9 Moreover, we added two uncommon 
components in evidence mapping, which were previously 
reported: the methodological quality assessment of SRs and 
the classification of the conclusions as beneficial, probably 
beneficial, no differential effect, inconclusive or harmful 
according to the results reported by authors.12 It has been 
suggested that this approach allows locating the results of 
one study in relation to other studies with the same com-
parison on a bubble plot, obtaining a broader outlook of 
the available evidence and its quality.12
The results of this evidence mapping show that in 
line with available evidence, there is a sprinkling of SRs 
about therapeutic interventions for oral cancer, since only 
15 SRs focusing on different therapies met the criteria. 
Moreover, most SRs included a small number of primary 
studies; thus, it may suggest that the evidence of this issue 
is limited. However, we wish to highlight that most of the 
primary studies included in this evidence mapping were 
RCTs, which is an aspect with clinical relevance because 
experimental studies are the best design to evaluate the 
efficacy of new therapeutic options.30 We also highlight 
that no comparison was reported as “harmful”, which is 
probably because most RCTs with negative conclusions 
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According to methodological quality assessment, most 
of the SRs scored “Critically low” methodology quality 
with the AMSTAR-2 tool. This indicates that there is room 
for a potential improvement of the quality of SRs in this 
field. Among the domains to improve are the inclusion of 
an explicit statement indicating that the SR methods were 
established prior to the conduct of the SR, as well as the 
inclusion of a report justifying any significant deviations 
from the protocol; the explanation of the selection of the 
study designs for inclusion in the SR; the provision of the 
list of excluded studies and justifying the exclusions; and the 
reporting of the conflicts of interests, indicating the source of 
funding or support for each of the included studies. Although 
the methodological quality assessment is not a core task of 
an evidence mapping, it has been suggested that any type of 
review should include this process in order to evaluate the 
consistency of its conclusions.6,12
In this evidence mapping, the main therapeutic interven-
tions reported by the authors as beneficial for patients with 
resectable oral cancer are surgery alone or in combination 
with radiotherapy or chemotherapy, depending on the extent 
of the disease. These results were based on SRs15,17,18,20,26,28,29 
with “Critically low” to “High” methodological quality 
evaluated with AMSTAR-2 tool. However, these reports 
should be taken with caution because some SRs15,28,29 only 
included observational studies. Moreover, despite the fact that 
some interventions reported by the authors as “beneficial” 
were based on RCTs,32–39 the majority of these comparisons 
included just one RCT,32,35,36 some of which had a small 
sample size.
There were fewer comparisons for patients with unre-
sectable oral cancer than for those with resectable oral 
cancer. Only two interventions were reported by the authors 
as beneficial; these found altered fractionated radiotherapy 
to be superior to other forms of radiotherapy16 and to the 
use of bleomycin as a chemotherapy drug.20 We wish to 
emphasize that all comparisons for this population were 
based on SRs16,18,20,21,23,25 including only RCTs and con-
trolled clinical trials. Nevertheless, these results should 
be placed in context. Firstly, despite the fact that altered 
fractionated radiotherapy was reported as a beneficial 
treatment for oral cancer, there is a previous report40 of 
the same SR16 that shows the same outcomes, but there 
are some numeric inconsistencies in the results between 
these reports, even though the same authors included the 
same studies in the analysis. For these reasons, we con-
tacted the authors and they clarified that the latest report 
had probably reclassified patients and provided the most 
accurate estimates. Secondly, recommending the use of 
bleomycin was based on only one single RCT41 published 
long time ago. Thus, nowadays, it is likely that there are 
other options for chemotherapy. For example, 5-fluoro-
uracil, cisplatin, carboplatin, paclitaxel and docetaxel are 
among the chemotherapy drugs most often used for oral 
and oropharyngeal cancers; these may be used alone or 
combined with other drugs.42,43
We were able to identify some research gaps on this topic 
such as targeted therapy, since just only one RCT44 addressing 
this topic was included in one SR.18 Moreover, despite a sharp 
increase in research into molecularly targeted therapies and 
a rapid expansion in the number of trials assessing new tar-
geted therapies, their value for treating oral cancers remains 
unclear. The advantage that these therapies may have over 
conventional chemotherapy is that rather than affecting both 
healthy and cancerous cells, they target only cancer cells.18 
Recently, de Felice and Guerrero Urbano 45 reviewed the 
published clinical trials about a specific targeted therapy and 
suggested that it could become a “central player” in head and 
neck cancers as it offers a potential therapeutic opportunity. 
Likewise, the same authors claimed that despite the ongoing 
trials, clinical data are lacking.
This evidence mapping can be used to help with the 
interpretation of published research syntheses, such as 
SRs and meta-analyses, and it can also be used as a tool to 
engage stakeholders. Similarly, it can be used to address 
future research projects focused on knowledge gaps identi-
fied with this evidence mapping, as well as to conduct SRs 
and RCTs focused on new therapeutic interventions for oral 
cancer. It is useful to clarify that this evidence mapping 
does not intend to replace any clinical protocol or guideline. 
Its aim is to describe the available evidence on therapeutic 
interventions for oral cancers; thus, any recommendations 
and practice points should be considered in the context of 
clinical judgment for each patient, the available alternatives 
and their risk/benefit ratio, the available resources and other 
contextual factors.46
Among the strengths of this study, we highlight that a 
sensitive search strategy was performed, so it is unlikely that 
any relevant studies were missed. Likewise, two reviewers 
independently conducted the whole processes of selection, 
methodological quality assessment and data extraction from 
the included SRs. All these processes provide reasonable 
confidence in these results.
Certain limitations in this evidence mapping should 
be taken into account. Firstly, there were limited SRs 
comparing therapeutic interventions for oral cancer, and 
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some of them included only observational studies; thus, 
some bias due to confounding factor may exist in these 
studies. Secondly, since some SRs had methodological 
limitations, their conclusions can be subject to bias; there-
fore, their conclusions regarding the effectiveness of the 
different interventions could be invalid. However, this is 
thoroughly reported in our results, so each conclusion can 
be assessed by the reader including its limitation. Other 
limitation is the language barrier; all the included SRs 
were published in English, which eliminated the inclusion 
into this mapping of available evidence published in any 
other language.
Conclusion
There is limited available evidence about therapeutic inter-
ventions for oral cancer. The methodological quality of 
most included SRs in this mapping scored “Critically low” 
quality with AMSTAR-2 tool. The main beneficial thera-
peutic interventions reported by authors for patients with 
resectable oral cancer are surgery alone or in combination 
with radiotherapy or chemotherapy. Evidence for the ben-
efits of treatments for unresectable oral cancer is lacking. 
These findings highlight the need to address future research 
focused on new therapeutic interventions and knowledge 
gaps in this field, as well as increased efforts are required 
to improve the methodology quality and reporting process 
of SRs on treatments for oral cancer. The evidence mapping 
is an adequate and reliable methodology to identify the 
current available evidence about therapeutic interventions.
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